DSGN: Design Therapeutics Price to Net Income Growth Ratio
Design Therapeutics is implementing revolutionary GeneTACs to combat Fuchs' dystrophy and ataxia, aiming for patent dominance. By analyzing the PEG fair value dynamics on GURU.Markets, we observe that the value of 0.00 expresses the metric level. Market capitalization is based on the development of gene therapies for hereditary pathologies, while environmental policy relies on strict biosafety controls and waste disposal.
Analytical breakdowns for Design Therapeutics (DSGN)
- price and consensus price forecast:
- market capitalization information:
- book capitalization data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Capital Design Therapeutics|DSGN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital designtx.com|DSGN - Company Aggregate Debts|Debts to Book Value Design Pharma|DSGN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Design Therapeutics|Quick Ratio designtx.com
- net income and valuation multiples indicators:
DSGN - Company Net Income|Forward Earnings Design Therapeutics|DSGN - P/E Multiple|Projected Price to Earnings Ratio Design Corp|DSGN - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Design Pharma|DSGN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Design Therapeutics|DSGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months designtx.com|DSGN - Earnings growth in current year|Expected earnings per share growth for next year Design Therapeutics
General company analysis:DSGN - Design Therapeutics Inc
Complex biosample logistics in Design Therapeutics (DSGN) research directly impact business growth rates, which is reflected in the history of the PEG ratio. This indicator divides the P/E multiple by the expected earnings growth rate, allowing for the identification of undervalued assets when the value is below one, where expansion potential outweighs the current market value of the shares.
Competitors of Design Therapeutics
Growth-Adjusted Market Cap to Net Income Tempus AI, Inc|PEG Multiple QGEN (Qiagen Group)|Price to Net Income Growth Ratio Isis Pharmaceuticals|RGEN - Price/Earnings to Growth Ratio|RNA (aviditybiosciences.com) - Growth-Adjusted P/E Ratio|CRSP (CRISPR Therapeutics) - Price/Earnings to Growth Multiple|GeneDx Holdings - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple RARE|BEAM (Beam Tx) - Company Value to Earnings Growth Ratio|PEG Multiple SRPT|TWST (twistbioscience.com) - Growth-Adjusted Payback Ratio|PEG Multiple TXG (10x Genomics)|Intellia Therapeutics Inc (NTLA) - Price to Earnings Adjusted for Growth Rate|STOK - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio BLFS (BioLife)|WVE: PEG Multiple|mazetx.com (MAZE) - PEG Multiple|Price/Earnings to Growth Ratio Sionna Therapeutics|Prime Medicine Inc - Market Cap to Earnings and Growth Ratio|PEG Multiple TSHA|QURE - Price to Earnings Adjusted for Growth Rate|MeiraGTx Holdings plc - Price/Earnings to Growth Multiple|PEG Multiple regenxbio.com RGNX|SLDB: Price/Earnings to Growth Multiple|Ocugen Inc - Company Value to Earnings Growth Ratio|PACB: PEG Multiple|BNTC - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharmaceuticals) - PEG Multiple|Price/Earnings to Growth Multiple 4dmoleculartherapeutics.com (FDMT)|Price/Earnings to Growth Ratio Lexeo Therapeutics (LXEO)|Growth-Adjusted Market Cap to Net Income korrobio.com|PEG Multiple EDIT (Editas)|SLN: Growth-Adjusted P/E Ratio|PRQR - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Codexis, Inc. CDXS|SGMO: PEG Multiple|Price to Net Income Growth Ratio Nautilus Bio NAUT|Price/Earnings to Growth Ratio Metagenomi, Inc|Growth-Adjusted P/E Ratio DTIL (Precision BioSciences Inc.)|PEG Multiple GBIO|boundlessbio.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure XCUR|IMNN: Growth-Adjusted P/E Ratio|RXi Pharmaceuticals - PEG Multiple|MBIO - PEG Multiple|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate bluebird bio Inc. BLUE|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|Growth-Adjusted Market Cap to Net Income Omega Therapeutics Corp|PEG Multiple OMIC (Singular Genomics Systems)|Growth-Adjusted Market Cap to Net Income regulusrx.com (RGLS)|Syros Pharmaceuticals, Inc. - PEG Multiple|Price to Net Income Growth Ratio Telesis Bio Inc. (TBIO)|TRACON (TCON) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio UBX
